– Post-hoc analysis of GENERATION HD1 study data showed tominersen may have potential benefit in a subgroup of patients – Ionis’ partner Roche is in early stages of designing trial for younger adult patient population with less disease burden – Partner to participate in series of webinars for
Ionis to present at 40th Annual J.P. Morgan Healthcare conference
CARLSBAD, Calif. , Jan. 5, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview at the virtual 40 th Annual J.P. Morgan Healthcare Conference at 9:45 a.m.
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
– BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervals – Biogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif. , Jan. 4, 2022 /PRNewswire/ — Biogen Inc.
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
CARLSBAD, Calif. , Dec. 29, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational antisense medicine for the
Ionis and AstraZeneca to develop and commercialize eplontersen
– Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market – The companies will jointly develop and commercialize eplontersen in the U.S., AstraZeneca has exclusive rights to commercialize in rest of the world – Bolsters Ionis’ commercial